Deals
Thermo Fisher Considers Buying $8 Billion Diagnostics Firm Qiagen
- Thermo Fisher has approached molecular testing firm about deal
- Purchase of Dutch firm would be among Thermo Fisher’s largest
Photographer: Jasper Juinen/Bloomberg
This article is for subscribers only.
Qiagen NV shares jumped the most in 17 years after people with knowledge of the matter said Thermo Fisher Scientific Inc. is considering a takeover of the molecular testing firm.
Thermo Fisher has approached the Dutch company about a potential purchase that could become one of its biggest-ever acquisitions, the people said, asking not to be identified because the information is private. Shares of Qiagen rose 13% to 33.20 euros at 1:10 p.m. in Frankfurt, giving it a market value of $8.3 billion.